Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.
Oncology (2019) Vol. 97, Iss. 5, pp. 277-285
Closed Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

Targeted therapy for hepatocellular carcinoma
Ao Huang, Xin–Rong Yang, Wen Yuan Chung, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 550
Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials
Donghua Shi, Yao Shi, Ahmed O. Kaseb, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 15, pp. 3979-3989
Open Access | Times Cited: 254
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
Masatoshi Kudo, Kwang–Hyub Han, Sheng-Long Ye, et al.
Liver Cancer (2020) Vol. 9, Iss. 3, pp. 245-260
Open Access | Times Cited: 240
Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update
Masatoshi Kudo
Liver Cancer (2020) Vol. 9, Iss. 6, pp. 640-662
Open Access | Times Cited: 94
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Cancer Reports (2021) Vol. 5, Iss. 2
Open Access | Times Cited: 59
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice
Takaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada, et al.
Hepatology Research (2022) Vol. 52, Iss. 9, pp. 773-783
Open Access | Times Cited: 56
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Oncology (2023) Vol. 101, Iss. 10, pp. 624-633
Closed Access | Times Cited: 24
Lenvatinib for Hepatocellular Carcinoma: A Literature Review
Takeshi Hatanaka, Atsushi Naganuma, Satoru Kakizaki
Pharmaceuticals (2021) Vol. 14, Iss. 1, pp. 36-36
Open Access | Times Cited: 53
Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis
Jaekyung Cheon, Hong Jae Chon, Yeonghak Bang, et al.
Liver Cancer (2020) Vol. 9, Iss. 5, pp. 613-624
Open Access | Times Cited: 51
EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis
Kazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, et al.
Liver Cancer (2020) Vol. 9, Iss. 6, pp. 734-743
Open Access | Times Cited: 51
Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Cancer Medicine (2022) Vol. 12, Iss. 1, pp. 325-334
Open Access | Times Cited: 37
Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.
Oncology (2019) Vol. 97, Iss. 6, pp. 334-340
Closed Access | Times Cited: 44
Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib
Atsushi Hiraoka, Takashi Kumada, Shinya Fukunishi, et al.
Liver Cancer (2019) Vol. 9, Iss. 1, pp. 73-83
Open Access | Times Cited: 43
Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting
Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, et al.
Journal of Gastroenterology and Hepatology (2020) Vol. 36, Iss. 7, pp. 1812-1819
Open Access | Times Cited: 43
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Hepatology Research (2021) Vol. 52, Iss. 3, pp. 308-316
Open Access | Times Cited: 37
Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma
Kazufumi Kobayashi, Sadahisa Ogasawara, Aya Takahashi, et al.
Liver Cancer (2021) Vol. 11, Iss. 1, pp. 48-60
Open Access | Times Cited: 37
Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study
Bin Xu, San-Yuan Dong, Xueli Bai, et al.
Liver Cancer (2022) Vol. 12, Iss. 3, pp. 262-276
Open Access | Times Cited: 24
Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment
Issei Saeki, Takahiro Yamasaki, Satoyoshi Yamashita, et al.
Cancers (2020) Vol. 12, Iss. 4, pp. 779-779
Open Access | Times Cited: 37
Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade
Takashi Kumada, Hidenori Toyoda, Toshifumi Tada, et al.
Liver Cancer (2020) Vol. 9, Iss. 5, pp. 518-528
Open Access | Times Cited: 35
Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib
Dong Dong, Jinyu Shi, Xiao Shang, et al.
Medicine (2022) Vol. 101, Iss. 5, pp. e28680-e28680
Open Access | Times Cited: 19
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancer Reports (2024) Vol. 7, Iss. 4
Open Access | Times Cited: 4
Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma
Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, et al.
Hepatology Research (2019) Vol. 50, Iss. 3, pp. 374-381
Closed Access | Times Cited: 32
Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy
Nobutaka Sato, Toru Beppu, Koichi Kinoshita, et al.
Anticancer Research (2019) Vol. 39, Iss. 10, pp. 5695-5701
Open Access | Times Cited: 31
Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Oncology (2020) Vol. 98, Iss. 5, pp. 295-302
Closed Access | Times Cited: 28
Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
Xinhua Zou, Qingyu Xu, Ran You, et al.
Advances in Therapy (2023) Vol. 40, Iss. 4, pp. 1686-1704
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top